JP2017513842A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017513842A5 JP2017513842A5 JP2016561879A JP2016561879A JP2017513842A5 JP 2017513842 A5 JP2017513842 A5 JP 2017513842A5 JP 2016561879 A JP2016561879 A JP 2016561879A JP 2016561879 A JP2016561879 A JP 2016561879A JP 2017513842 A5 JP2017513842 A5 JP 2017513842A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- optionally substituted
- atom
- salt
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014082057 | 2014-04-11 | ||
| JP2014082057 | 2014-04-11 | ||
| PCT/JP2015/061651 WO2015156417A1 (en) | 2014-04-11 | 2015-04-09 | Cyclopropanamine compound and use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017513842A JP2017513842A (ja) | 2017-06-01 |
| JP2017513842A5 true JP2017513842A5 (enExample) | 2018-05-24 |
| JP6470310B2 JP6470310B2 (ja) | 2019-02-13 |
Family
ID=53055078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016561879A Expired - Fee Related JP6470310B2 (ja) | 2014-04-11 | 2015-04-09 | シクロプロパンアミン化合物およびその用途 |
Country Status (28)
| Country | Link |
|---|---|
| US (9) | US10053456B2 (enExample) |
| EP (1) | EP3129369A1 (enExample) |
| JP (1) | JP6470310B2 (enExample) |
| KR (1) | KR102359836B1 (enExample) |
| CN (1) | CN106459024B (enExample) |
| AR (1) | AR099994A1 (enExample) |
| AU (1) | AU2015244698B2 (enExample) |
| BR (1) | BR112016023382B1 (enExample) |
| CA (1) | CA2945085C (enExample) |
| CL (1) | CL2016002573A1 (enExample) |
| CR (1) | CR20160485A (enExample) |
| DO (1) | DOP2016000273A (enExample) |
| EA (1) | EA034197B1 (enExample) |
| EC (1) | ECSP16087256A (enExample) |
| IL (1) | IL248181B (enExample) |
| MA (1) | MA39732A (enExample) |
| MX (1) | MX375990B (enExample) |
| MY (1) | MY180575A (enExample) |
| NZ (1) | NZ725262A (enExample) |
| PE (1) | PE20161441A1 (enExample) |
| PH (1) | PH12016502016B1 (enExample) |
| SG (2) | SG10201808780YA (enExample) |
| TN (1) | TN2016000418A1 (enExample) |
| TW (1) | TWI669291B (enExample) |
| UA (1) | UA122205C2 (enExample) |
| UY (1) | UY36071A (enExample) |
| WO (1) | WO2015156417A1 (enExample) |
| ZA (1) | ZA201607773B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3105218T (lt) | 2014-02-13 | 2019-12-10 | Incyte Corp | Ciklopropilaminai kaip lsd1 inhibitoriai |
| EP3392244A1 (en) | 2014-02-13 | 2018-10-24 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| WO2015123424A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| NZ725262A (en) | 2014-04-11 | 2023-01-27 | Takeda Pharmaceuticals Co | Cyclopropanamine compound and use thereof |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
| WO2016007736A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyrazines as lsd1 inhibitors |
| US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
| US11369577B2 (en) | 2014-11-26 | 2022-06-28 | IEO—Istituto Europeo di Oncologia S.r.l. | Reprogramming-based models of neurodevelopmental disorders and uses thereof |
| EA201792205A1 (ru) | 2015-04-03 | 2018-02-28 | Инсайт Корпорейшн | Гетероциклические соединения как ингибиторы lsd1 |
| KR20180011331A (ko) | 2015-06-12 | 2018-01-31 | 오리존 지노믹스 에스.에이. | Lsd1 억제제와 관련된 바이오마커 및 그의 용도 |
| WO2017013061A1 (en) | 2015-07-17 | 2017-01-26 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| DK3334709T3 (da) | 2015-08-12 | 2025-02-03 | Incyte Holdings Corp | Salte af en lsd1-hæmmer |
| WO2017079476A1 (en) | 2015-11-05 | 2017-05-11 | Mirati Therapeutics, Inc. | Lsd1 inhibitors |
| KR102720551B1 (ko) | 2015-12-29 | 2024-10-21 | 미라티 테라퓨틱스, 인크. | Lsd1 억제제 |
| KR20180099768A (ko) | 2015-12-30 | 2018-09-05 | 노파르티스 아게 | 증진된 효능을 갖는 면역 이펙터 세포 요법 |
| JPWO2017130933A1 (ja) * | 2016-01-25 | 2018-11-29 | 国立大学法人 熊本大学 | 神経変性疾患治療剤 |
| CN120661674A (zh) | 2016-03-15 | 2025-09-19 | 奥莱松基因组股份有限公司 | 用于治疗实体瘤的lsd1抑制剂的组合 |
| JP2019512546A (ja) | 2016-03-16 | 2019-05-16 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Ｋｄｍ１ａ標的会合を決定するための方法、およびそれに有用な化学プローブ |
| CA3021678A1 (en) | 2016-04-22 | 2017-10-26 | Incyte Corporation | Formulations of an lsd1 inhibitor |
| US20190256929A1 (en) | 2016-11-03 | 2019-08-22 | Oryzon Genomics, S.A. | Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents |
| US20190256930A1 (en) | 2016-11-03 | 2019-08-22 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
| AU2018309372B2 (en) | 2017-08-03 | 2024-08-15 | Oryzon Genomics, S.A. | Methods of treating behavior alterations |
| US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
| CN109553591B (zh) * | 2019-01-15 | 2020-12-15 | 山东安信制药有限公司 | 一种富马酸喹硫平中间体的制备方法 |
| HRP20251471T1 (hr) | 2019-03-20 | 2026-01-02 | Oryzon Genomics, S.A. | Postupci liječenja poremećaja hiperaktivnosti s deficitom pažnje korištenjem inhibitora kdm1a kao što je spoj vafidemstat |
| SI3941466T1 (sl) | 2019-03-20 | 2026-04-30 | Oryzon Genomics, S.A. | Vafidemstat za zdravljenje neagresivnih simptomov mejne osebnostne motnje |
| CN114341366A (zh) | 2019-07-05 | 2022-04-12 | 奥莱松基因组股份有限公司 | 用于使用kdm1a抑制剂个体化治疗小细胞肺癌的生物标志物和方法 |
| WO2022224267A1 (en) * | 2021-04-21 | 2022-10-27 | Natco Pharma Limited | Improved process for the preparation of 7-(morpholinyl)-2-(n-piperazinyl)methylthieno[2, 3-c]pyridine derivatives |
| CN113512031B (zh) * | 2021-07-01 | 2024-01-30 | 都创(上海)医药开发有限公司 | 一种lsd1酶抑制剂tak-418中间体化合物制备方法 |
| CN117164465B (zh) * | 2023-09-04 | 2025-07-01 | 郑州大学 | 一种苯基环丙胺类化合物及其制备方法和应用 |
| WO2026060261A1 (en) * | 2024-09-13 | 2026-03-19 | Equator Therapeutics, Inc. | Compositions and methods for treating metabolic disorders |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1395257A1 (en) | 2001-06-12 | 2004-03-10 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
| GB0316915D0 (en) | 2003-07-18 | 2003-08-20 | Glaxo Group Ltd | Compounds |
| CN1882529A (zh) | 2003-09-24 | 2006-12-20 | 梅特希尔基因公司 | 组蛋白脱乙酰基酶抑制剂 |
| AU2004276337B2 (en) | 2003-09-24 | 2009-11-12 | Methylgene Inc. | Inhibitors of histone deacetylase |
| ZA200605248B (en) | 2003-12-15 | 2007-10-31 | Japan Tobacco Inc | Cyclopropane compounds and pharmaceutical use thereof |
| WO2010043721A1 (en) | 2008-10-17 | 2010-04-22 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
| US8993808B2 (en) * | 2009-01-21 | 2015-03-31 | Oryzon Genomics, S.A. | Phenylcyclopropylamine derivatives and their medical use |
| US8389580B2 (en) | 2009-06-02 | 2013-03-05 | Duke University | Arylcyclopropylamines and methods of use |
| JPWO2010143582A1 (ja) * | 2009-06-11 | 2012-11-22 | 公立大学法人名古屋市立大学 | フェニルシクロプロピルアミン誘導体及びｌｓｄ１阻害剤 |
| WO2011035941A1 (en) | 2009-09-25 | 2011-03-31 | Oryzon Genomics S.A. | Lysine specific demethylase-1 inhibitors and their use |
| US8946296B2 (en) * | 2009-10-09 | 2015-02-03 | Oryzon Genomics S.A. | Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use |
| RS55348B1 (sr) | 2010-04-19 | 2017-03-31 | Oryzon Gnomics S A | Inhibitori lizin specifične demetilaze-1 i njihova upotreba |
| US8765820B2 (en) | 2010-04-20 | 2014-07-01 | Universita Degli Studi Di Roma “La Sapienza” | Tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and/or LSD2 |
| EP2598480B1 (en) * | 2010-07-29 | 2019-04-24 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as lsd1 inhibitors |
| DK2598482T3 (en) | 2010-07-29 | 2018-06-14 | Oryzon Genomics Sa | ARYLCYCLOPROPYLAMINE-BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE |
| JP2012036124A (ja) | 2010-08-06 | 2012-02-23 | Nagoya City Univ | Ｈｉｖ複製阻害剤 |
| WO2012022047A1 (en) * | 2010-08-20 | 2012-02-23 | Tongji University | Rod system for gradual dynamic spinal fixation |
| WO2012045883A1 (en) | 2010-10-08 | 2012-04-12 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
| MX347913B (es) | 2011-03-25 | 2017-05-17 | Glaxosmithkline Intellectual Property (No 2) Ltd | Ciclopropilaminas como inhibidores de desmetilasa 1 especifica de lisina. |
| EP2750671A2 (en) | 2011-05-19 | 2014-07-09 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for thrombosis and cardiovascular diseases |
| WO2012156531A2 (en) | 2011-05-19 | 2012-11-22 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for inflammatory diseases or conditions |
| BR112014002939A2 (pt) | 2011-08-09 | 2017-03-01 | Takeda Pharmaceuticals Co | composto, medicamento, método para profilaxia ou tratamento de doença, a doença sendo esquizofrenia, alzheimer, parkinson ou huntington, uso do composto, e, método para inibir o lsd1 |
| US9469597B2 (en) | 2011-10-20 | 2016-10-18 | Oryzon Genomics S.A. | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors |
| AU2012324803B9 (en) | 2011-10-20 | 2017-08-24 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as LSD1 inhibitors |
| EP2907802B1 (en) * | 2012-10-12 | 2019-08-07 | Takeda Pharmaceutical Company Limited | Cyclopropanamine compound and use thereof |
| CN104042616B (zh) | 2014-02-20 | 2016-08-24 | 复旦大学附属眼耳鼻喉科医院 | 赖氨酸特异性去甲基化酶1抑制剂的应用 |
| NZ725262A (en) * | 2014-04-11 | 2023-01-27 | Takeda Pharmaceuticals Co | Cyclopropanamine compound and use thereof |
| WO2015168149A2 (en) | 2014-04-28 | 2015-11-05 | Massachusetts Eye & Ear Infirmary | Sensorineural hair cell differentiation |
-
2015
- 2015-04-09 NZ NZ725262A patent/NZ725262A/en unknown
- 2015-04-09 TN TN2016000418A patent/TN2016000418A1/en unknown
- 2015-04-09 TW TW104111396A patent/TWI669291B/zh active
- 2015-04-09 EP EP15721046.9A patent/EP3129369A1/en not_active Withdrawn
- 2015-04-09 MX MX2016013369A patent/MX375990B/es active IP Right Grant
- 2015-04-09 CA CA2945085A patent/CA2945085C/en active Active
- 2015-04-09 UA UAA201611450A patent/UA122205C2/uk unknown
- 2015-04-09 SG SG10201808780YA patent/SG10201808780YA/en unknown
- 2015-04-09 KR KR1020167029899A patent/KR102359836B1/ko active Active
- 2015-04-09 PE PE2016001947A patent/PE20161441A1/es unknown
- 2015-04-09 SG SG11201608340UA patent/SG11201608340UA/en unknown
- 2015-04-09 US US15/302,405 patent/US10053456B2/en active Active
- 2015-04-09 CR CR20160485A patent/CR20160485A/es unknown
- 2015-04-09 EA EA201692052A patent/EA034197B1/ru not_active IP Right Cessation
- 2015-04-09 US US14/682,695 patent/US9487511B2/en active Active
- 2015-04-09 CN CN201580031044.3A patent/CN106459024B/zh active Active
- 2015-04-09 PH PH1/2016/502016A patent/PH12016502016B1/en unknown
- 2015-04-09 MY MYPI2016703700A patent/MY180575A/en unknown
- 2015-04-09 BR BR112016023382-4A patent/BR112016023382B1/pt active IP Right Grant
- 2015-04-09 AU AU2015244698A patent/AU2015244698B2/en active Active
- 2015-04-09 UY UY0001036071A patent/UY36071A/es not_active Application Discontinuation
- 2015-04-09 MA MA039732A patent/MA39732A/fr unknown
- 2015-04-09 JP JP2016561879A patent/JP6470310B2/ja not_active Expired - Fee Related
- 2015-04-09 AR ARP150101073A patent/AR099994A1/es active IP Right Grant
- 2015-04-09 WO PCT/JP2015/061651 patent/WO2015156417A1/en not_active Ceased
-
2016
- 2016-07-06 US US15/203,522 patent/US9718814B2/en not_active Expired - Fee Related
- 2016-07-06 US US15/203,551 patent/US9714241B2/en not_active Expired - Fee Related
- 2016-09-20 US US15/270,863 patent/US9920047B2/en active Active
- 2016-10-05 IL IL248181A patent/IL248181B/en active IP Right Grant
- 2016-10-07 DO DO2016000273A patent/DOP2016000273A/es unknown
- 2016-10-07 CL CL2016002573A patent/CL2016002573A1/es unknown
- 2016-11-10 ZA ZA2016/07773A patent/ZA201607773B/en unknown
- 2016-11-11 EC ECIEPI201687256A patent/ECSP16087256A/es unknown
-
2018
- 2018-01-29 US US15/882,386 patent/US10414761B2/en active Active
-
2019
- 2019-06-27 US US16/455,359 patent/US10968213B2/en active Active
-
2021
- 2021-02-16 US US17/176,861 patent/US20210179603A1/en not_active Abandoned
-
2023
- 2023-08-14 US US18/449,326 patent/US20240317733A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20161441A1 (es) | Compuesto de ciclopropanamina y sus usos | |
| CO2019007711A2 (es) | N-[4-fluoro-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga | |
| AR063451A1 (es) | Diazabiciclo alcanos como receptores nicotinicos de acetilcolina. composiciones farmaceuticas. | |
| JP2014523851A5 (enExample) | ||
| CA2887598A1 (en) | Cyclopropanamine compound and use thereof | |
| JP2016505637A5 (enExample) | ||
| JP2017538785A5 (enExample) | ||
| BR112014026643A2 (pt) | derivados de imidazotiadiazol e imidazopirazina como inibidores de receptor 4 ativado por protease (par4) para o tratamento de agregação de plaqueta | |
| NZ604831A (en) | Apoptosis signal-regulating kinase inhibitors | |
| JP2014514286A5 (enExample) | ||
| JP2019525899A5 (enExample) | ||
| JP2013525444A5 (enExample) | ||
| JP2015516427A5 (enExample) | ||
| JP2010526106A5 (enExample) | ||
| JP2013063968A5 (enExample) | ||
| NZ598750A (en) | Therapeutic agent for mood disorders | |
| SI1919465T1 (en) | GSK-3 INHIBITORS | |
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
| HRP20191744T1 (hr) | 1-[2-(aminometil)benzil]-2-tiokso-1,2,3,5-tetrahidro-4h-pirolo[3,2-d]pirimidin-4-oni kao inhibitori mijeloperoksidaze | |
| JP2017500289A5 (enExample) | ||
| JP2017505293A5 (enExample) | ||
| JP2013539774A5 (enExample) | ||
| RU2015101210A (ru) | Производные тиофена, используемые для лечения сахарного диабета | |
| JP2016540811A5 (enExample) | ||
| EP3999181C0 (en) | POLYMORPHS OF (R)-N-(5-(5-ISOPROPYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-2-METHYL-2H-TETRAZOLE-5-CARBOXAMIDE |